DOI QR코드

DOI QR Code

Benefit of volumetric-modulated arc therapy over three-dimensional conformal radiotherapy for stage I-II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the stomach: a dosimetric comparison

  • Chung, Joo-Hyun (Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Na, Kyoungsu (Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Kim, Il Han (Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine)
  • Received : 2018.08.28
  • Accepted : 2018.11.27
  • Published : 2018.12.31

Abstract

Purpose: To retrospectively analyze dosimetric parameters of volumetric-modulated arc therapy (VMAT) and three-dimensional conformal radiotherapy (3D-CRT) delivered to extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue in the stomach (gastric MALT lymphoma) to find out advantages of VMAT and conditions for definite benefits of VMAT. Materials and Methods: Fifty patients with stage I-II gastric MALT lymphoma received VMAT (n = 14) or 3D-CRT (n = 36) between December 2005 and April 2018. Twenty-seven patients were categorized according to whether the planning target volume (PTV) overlaps kidney(s). Dosimetric parameters were analyzed by dose-volume histogram. Results: Radiation dose to the liver was definitely lower with VMAT in terms of mean dose (p = 0.026) and V15 (p = 0.008). The V15 of the left kidney was lower with VMAT (p = 0.065). For those with PTV overlapping kidney(s), the left kidney V15 was significantly lower with VMAT. Furthermore, the closer the distance between the PTV and kidneys, the less the left kidney V15 with VMAT (p = 0.037). Delineation of kidney(s) by integrating all respiratory phases had no additional benefit. Conclusions: VMAT significantly increased monitor units, reduced treatment time and radiation dose to the liver and kidneys. The benefit of VMAT was definite in reducing the left kidney V15, especially in geometrically challenging conditions of overlap or close separation between PTV and kidney(s).

Keywords

References

  1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
  2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
  3. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosaassociated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16:1916-21.
  4. Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach: a review of treatment options. Int J Radiat Oncol Biol Phys 2000;46:1093-103.
  5. Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005;23:7050-9.
  6. Lin ML, Wirth A, Chao M, et al. Radiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study. Intern Med J 2007;37:172-80.
  7. Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol 2008;87:405-11.
  8. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010;116:3815-24.
  9. Wirth A, Gospodarowicz M, Aleman BM, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 2013;24:1344-51.
  10. Zelenetz AD, Hoppe RT; NCCN Non-Hodgkin's Lymphoma Practice Guidelines Panel. NCCN: non-Hodgkin's lymphoma. Cancer Control 2001;8(6 Suppl 2):102-13.
  11. Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015;92:11-31.
  12. Della Biancia C, Hunt M, Furhang E, Wu E, Yahalom J. Radiation treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys 2005;62:745-51.
  13. Inaba K, Okamoto H, Wakita A, et al. Radiotherapy for gastric lymphoma: a planning study of 3D conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy. J Radiat Res 2014;55:1141-5.
  14. Bae SH, Kim DW, Kim MS, Shin MH, Park HC, Lim DH. Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma: dosimetric comparison and risk assessment of solid secondary cancer. Radiat Oncol J 2017;35:78-89.
  15. Nour AA, Alaradi A, Mohamed A, Altuwaijri S, Rudat V. Intensity modulated radiotherapy of upper abdominal malignancies: dosimetric comparison with 3D conformal radiotherapy and acute toxicity. Radiat Oncol 2013;8:207.
  16. Lim HW, Kim TH, Choi IJ, et al. Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dosevolumetric analysis and its clinical implications. Radiat Oncol J 2016;34:193-201.
  17. Ruben JD, Lancaster CM, Jones P, Smith RL. A comparison of out-of-field dose and its constituent components for intensity-modulated radiation therapy versus conformal radiation therapy: implications for carcinogenesis. Int J Radiat Oncol Biol Phys 2011;81:1458-64.
  18. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys 2006;64:333-42.
  19. Kataria T, Sharma K, Subramani V, Karrthick KP, Bisht SS. Homogeneity Index: an objective tool for assessment of conformal radiation treatments. J Med Phys 2012;37:207-13.
  20. Wang X, Li G, Zhang Y, et al. Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT). Med Dosim 2013;38:395-400.
  21. Adorante N, Perrotti F, Giancaterino S, et al. Dosimetric comparison of 3D-conformal radiotherapy, intensitymodulated radiotherapy and volumetric-modulated ARC therapy for upper abdominal tumors. Phys Med 2016;32(Suppl 1):A.01.
  22. Lee IJ, Seong J, Koom WS, et al. Selection of the optimal radiotherapy technique for locally advanced hepatocellular carcinoma. Jpn J Clin Oncol 2011;41:882-9.
  23. Chen D, Wang R, Meng X, et al. A comparison of liver protection among 3-D conformal radiotherapy, intensitymodulated radiotherapy and RapidArc for hepatocellular carcinoma. Radiat Oncol 2014;9:48.
  24. Kal HB, van Kempen-Harteveld ML. Renal dysfunction after total body irradiation: dose-effect relationship. Int J Radiat Oncol Biol Phys 2006;65:1228-32.
  25. Cheng JC, Schultheiss TE, Wong JY. Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys 2008;71:1436-43.

Cited by

  1. Low Expression of GLIS2 Gene Might Associate with Radiosensitivity of Gastric Cancer vol.2019, pp.None, 2018, https://doi.org/10.1155/2019/2934925
  2. Combining deep-inspiration breath hold and intensity-modulated radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma: Dosimetric evaluation using comprehensive plan quality indices vol.14, pp.1, 2018, https://doi.org/10.1186/s13014-019-1263-7
  3. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02 vol.37, pp.1, 2020, https://doi.org/10.1007/s10585-019-09992-z
  4. Analysis of Chronic Kidney Disease After Radiation Therapy for Gastric/Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma vol.6, pp.6, 2018, https://doi.org/10.1016/j.adro.2021.100788